In the GLP-1 weight loss space, Eli Lilly currently holds the pole position, surpassing Novo Nordisk. Novo Nordisk’s stock saw a significant surge after introducing its GLP-1 weight loss drugs but has since lost over two-thirds of its value. Meanwhile, Pfizer is aggressively re-entering the GLP-1 race after its internal candidate failed. Eli Lilly’s weight loss drug tirzepatide is leading the pack, with impressive sales growth, while Novo Nordisk is trailing behind. Pfizer aims to bounce back by expanding in the weight-loss space and enhancing its drug pipeline.

Pfizer is facing challenges with its COVID-19 vaccine sales slowing down and upcoming patent expirations. Despite this, the company is making bold moves to recover, especially in the GLP-1 space. Comparatively, Novo Nordisk’s stock has been on a downward trend since its peak in 2024. Pfizer’s lower valuation metrics make it an attractive contrarian play over Novo Nordisk. Investors may find Pfizer’s potential for a turnaround compelling, despite its current setbacks.

Pfizer’s high dividend yield may seem appealing, but its payout ratio is over 100%, indicating it’s more of a turnaround play than a dividend stock. Novo Nordisk’s lower yield and payout ratio may be a better choice for reliable dividends. The Motley Fool’s Stock Advisor team doesn’t include Novo Nordisk among the 10 best stocks to buy now, suggesting other opportunities for significant returns. Investors looking for long-term success in the pharmaceutical sector should consider Pfizer’s potential to bounce back and surprise the market with new drugs.

Read more at Nasdaq: Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?